argenx | News

The Latest

News

May 26, 2020

argenx Announces Positive Topline Phase 3 ADAPT Trial Results

Breda, the Netherlands / Ghent, Belgium

argenx today announced positive topline data from the pivotal ADAPT trial of efgartigimod. ADAPT met its primary endpoint defined as percentage of responders on the Myasthenia Gravis Activities of Daily Living (MG-ADL) score among acetylcholine receptor-antibody positive (AChR-Ab+) generalized myasthenia gravis (gMG) patients.

argenx Announces Positive Topline Phase 3 ADAPT Trial Results

argenx Announces Positive Topline Phase 3 ADAPT Trial Results

More Press Releases

News

June 3, 2020

argenx to Present at Goldman Sachs 41st Annual Global Healthcare Conference

argenx today announced that Tim Van Hauwermeiren, Chief Executive Officer, will participate in a fireside chat at the Goldman Sachs 41st Annual Global Healthcare Conference on Wednesday, June 10, 2020 at 8:00 a.m. ET.

News

June 1, 2020

argenx announces closing of global offering

argenx announced today the closing of its previously announced global offering of an aggregate of 4,207,292 ordinary shares (including ordinary shares represented by American Depositary Shares (ADSs)), which includes the full exercise of the underwriters’ option to purchase 548,777 additional ADSs.

News

May 29, 2020

argenx announces full exercise of underwriters’ option to purchase additional ADSs

argenx announced today that the underwriters of its previously announced global offering of ordinary shares have exercised their option to purchase 548,777 additional ADSs in full on the same terms and conditions as the global offering.

Media Center

April 7, 2020

SIMPLE Antibody platform / Combining Somatic Mutations Present in Different in Vivo Affinity-Matured Antibodies Isolated From Immunized Lama Glama Yields Ultra-Potent Antibody Therapeutics

April 7, 2020

SIMPLE Antibody platform / Camelid Ig V genes reveal significant human homology not seen in therapeutic target genes, providing for a powerful therapeutic antibody platform

April 7, 2020

SIMPLE Antibody platform / DNA immunization combined with scFv phage display identifies antagonistic GCGR specific antibodies and reveals new epitopes on the small extracellular loops

April 7, 2020

Cusatuzumab / CD70: An emerging target in cancer immunotherapy

April 7, 2020

Cusatuzumab / CD70/CD27 signaling promotes blast stemness and is a viable therapeutic target in acute myeloid leukemia